You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Cardiovascular Biomarkers in Hypertensive Patients with Medical Treatment—Results from the Randomized TEAMSTA Protect I Trial
Contributor:
Jagodzinski, Annika;
Neumann, Johannes Tobias;
Ojeda, Francisco;
Sörensen, Nils Arne;
Wild, Philipp;
Münzel, Thomas;
Zeller, Tanja;
Westermann, Dirk;
Blankenberg, Stefan
Published:
Oxford University Press (OUP), 2017
Published in:
Clinical Chemistry, 63 (2017) 12, Seite 1877-1885
Language:
English
DOI:
10.1373/clinchem.2017.275289
ISSN:
0009-9147;
1530-8561
Origination:
Footnote:
Description:
AbstractBACKGROUNDHigh blood pressure (BP) is associated with an increased rate of cardiovascular events and mortality. Cardiovascular biomarkers are able to predict long-term risk in the general population, particularly in diseased cohorts. We undertook an investigation of the effect of 2 different antihypertensive treatments on cardiovascular biomarkers in a randomized trial.METHODSThe TEAMSTA study included 481 hypertensive patients. They were randomized to either 80-mg telmisartan + 5-mg amlodipine (TA) or 40-mg olmesartan + 12.5-mg hydrochlorothiazide (OH). The trial was performed as a prospective, randomized, double-blinded, controlled, single-center study. We measured BP, high-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity cardiac troponin T (hs-cTnT), B-type natriuretic peptide (BNP), and N-terminal-pro-BNP (NT-proBNP) before randomization and after 6 months.RESULTSIndividuals were randomized into 2 groups: 230 individuals to the OH-group and 251 to the TA-group. After 6 months of treatment, a reduction in BP (systolic/diastolic) was seen, from 135.2/85.2 mmHg to 122.5/75.7 mmHg with similar effects in both groups. hs-cTnT concentrations were measureable in 26.2% of the study population, while hs-cTnI was detected in 98.3%. hs-cTnI concentrations were significantly reduced from 4.6 to 4.2 ng/L in the overall population, from 4.7 to 4.4 ng/L in the OH-group, and from 4.6 to 4.0 ng/L in the TA-group (all P < 0.001). No significant changes of hs-cTnT were observed. BNP and NT-proBNP concentrations decreased from 15.0 to 12.4 ng/L (P < 0.001) and from 64.8 to 53.3 ng/L (P < 0.001), respectively, after 6 months.CONCLUSIONSThe reduction in BP was associated with a decrease of high-sensitivity troponin I, BNP, and NT-proBNP concentrations, which might represent a cardiovascular risk reduction.CLINICAL TRIAL REGISTRATIONEudraCT 2009-017010-68